CompletedNot Applicable

Role of Montelukast in Preventing Relapse in Childhood Idiopathic Nephrotic Syndrome

Pakistan106 participantsStarted 2019-02-01

Plain-language summary

The investigators planned this research to elucidate if there is any efficacy of montelukast, a leukotriene receptor antagonist, in steroid sensitive childhood onset NS to help prevent relapses. This study was done to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)

Who can participate

Age range1 Year – 10 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria:A total of 106 children aged 1-10 years with idiopathic nephrotic syndrome were enrolled \- Exclusion Criteria: - Patients having Steroid resistant nephrotic syndrome (SRNS) or those having nephrotic syndrome with atypical features or Secondary cause were excluded.

What they're measuring

Prevention of relapse in idiopathic childhood nephrotic syndrome

Timeframe: 1 year

Trial details

NCT IDNCT04818723

SponsorNishtar Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-05-30

View on ClinicalTrials.gov More Nephrotic Syndrome trials